CodexisCDXS
CDXS logo
Fair Value
US$2
Share price12 Dec
US$1.4726.5% undervalued intrinsic discount
Loading
1Y-46.93%
7D5.00%

Rising siRNA Manufacturing Risks May Delay Profitability Yet Long-Term Upside Remains

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
12 Dec 25
Views
47
Not Invested

Fair Value vs Share Price

US$2
vs US$1.4726.5% undervalued intrinsic discount
PastFuture-76m139m2014201720202023202520262028Revenue US$116.5mEarnings US$18.1m
30.1%
Revenue growth
15.5%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Codexis

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

High growth potential with excellent balance sheet.

Market capUS$158.1m
PB3.7x
Estimated Growth20.4%
Dividend YieldN/A
Full analysis

CEO & management

Alison Moore
CEO
1.8yrs
CEO Tenure

Provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.